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Background: Postoperative nausea and vomiting (PONV) is one of the most common postsurgical complications.
Palonosetron, a 5-hydroxytryptamine receptor antagonist, is effective for PONV prevention. Herein, we compared
palonosetron and aprepitant (a neurokinin-1 receptor antagonist) for PONV prevention in patients indicated for
laparoscopic gynaecologic surgery.
Methods: Ninety-three patients who were scheduled to undergo laparoscopic gynaecologic surgery under general
anaesthesia were assigned to receive either a single intravenous injection of 0.075-mg palonosetron or 40-mg oral
aprepitant in a double-blind randomised trial. The primary efficacy end points included complete response (visual
analogue scale [VAS] nausea score <4 and no use of rescue therapy) 0–48 h after surgery. Nausea severity (0–10)
and use of rescue therapy were monitored for 0–48 h. The secondary efficacy end points were the effect of
aprepitant quantified using a 10-point VAS for pain, consumption of intravenous patient-controlled analgesia, and
use of rescue analgesics.
Results: Aprepitant was non-inferior to palonosetron in terms of complete response 0–48 hours after surgery (74%
vs. 77%). At 0 and 2 h after administration, the nausea severity with 40-mg aprepitant was significantly lesser than
that with 0.075-mg palonosetron (P < 0.05). At 6 and 24 h after administration, fentanyl consumption with 40-mg
aprepitant was significantly lower than that with 0.075-mg palonosetron. Greater amounts of rescue analgesics were
required in the aprepitant group.
Conclusions: Palonosetron and aprepitant were both effective for PONV prevention in the patients indicated for
laparoscopic gynaecologic surgery. The drugs can be used in combination for multimodal therapy because they
bind to different receptors. More research is needed to evaluate the effects of aprepitant on pain management
in humans.
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Postoperative nausea and vomiting (PONV) is one of the
most common postsurgical complications. It is caused by
various factors such as the use of anaesthetics, the use of
opioids for postoperative pain, the type of surgery, and pa-
tient characteristics [1]. PONV decreases patient satisfac-
tion with surgical outcomes, extends the hospitalisation
period because of delayed recovery, and causes fatal com-
plications, including suture laceration, bleeding, increased
intracranial pressure, aspiration pneumonia, dehydration,
and electrolyte imbalance [2].
The vomiting centre in the brain stem, which is com-
prised of the reticular formation and nucleus tractus
solitaries, can be activated directly via irritants or indir-
ectly via 4 principal areas, namely the gastrointestinal
tract, cerebral cortex and thalamus, vestibular region,
and chemoreceptor trigger zone [3]. These regions con-
tain high concentrations of opioid, dopamine, sero-
tonin (or 5-hydroxytryptamine), histamine, and muscarini
cholinergic receptor [4]. Various classes of medications,
including serotonin receptor antagonists, dopamine recep-
tor antagonists, and steroids, are currently used to prevent
PONV.
Among such medications, palonosetron (Aloxi in-
jection; CJ CheilJedang Corp., Seoul, Republic of Korea)
is a long-acting, second-generation serotonin receptor
antagonist that is one of the most commonly used
antiemetics for PONV prevention. Substance P or the
neurokinin-1 (NK1) receptor is also found in gastro-
intestinal vagal afferents and the nucleus tractus soli-
taries [5]. Its antagonist, aprepitant (Emend capsule;
MSD Korea Ltd., Seoul, Republic of Korea), was developed
to prevent chemotherapy-induced nausea and vomiting,
similar to other antiemetic drugs. Its efficacy in PONV
prevention was recently demonstrated [6,7].
The primary aim of this study was to confirm the equi-
valent effects of palonosetron and aprepitant on PONV
prevention. Eriksson and Korttila [8] reported that 80% of
patients who underwent gynaecologic laparoscopy de-
veloped PONV. Apfel et al. [9] suggested the following
PONV risk factors in adult patients who underwent gen-
eral anaesthesia: female sex, non-smoking status, history
of PONV and motion sickness, and perioperative opioid
use. This study compared the effects of 2 widely used
drugs for PONV prevention, namely palonosetron and
aprepitant, in female patients who were indicated to
undergo gynaecologic surgery.
Substance P is a neurotransmitter that is secreted
when a strong stimulus occurs in the body, and its func-
tion in pain-related signalling is well documented. An
animal study demonstrated the efficacy of aprepitant in
controlling pain [10]. Based on the study results, aprepi-
tant was suggested to affect postoperative pain and the
amount of opioids needed for pain control. Therefore,the present study additionally investigated the effect of
aprepitant on pain.
Methods
This study was conducted with patients, American
Society of Anesthesiologists physical status rating 1–2
and aged 20–60, who were scheduled to undergo laparo-
scopic gynaecologic surgery. Exclusion criteria were pa-
tients who were pregnant; weighed <45 or ≥100 kg; were
smokers; and had a history of PONV, other serious med-
ical ailment of the cardiovascular system, kidney, or liver,
or a hepatic disorder. This study was approved by the
Chung-Ang University Hospital Institutional Review
Board and registered at the Australia-New Zealand Clinical
Trials Registry (ACTRN12613000902796). The study ob-
jective, methods, and period, and the expected adverse
events were explained to the patients before obtaining their
consent for participation. Before surgery, the patients were
also educated on the visual analogue scale (VAS), a tool by
which nausea and pain are rated on a scale of 0 to 10, and
the intravenous patient-controlled analgesia (IV-PCA),
which would be used postoperatively.
The patients were divided into 2 groups using a ran-
dom number generator in Microsoft Excel. The aprepi-
tant group (group A) was given 40 mg of aprepitant
with 30 mL of water orally, 90 min before anaesthesia
induction. The patients were informed that the aprepi-
tant was a premedication for their operation and were
unaware that it was a study variable. All the patients in
both groups received 0.2 mg of glycopyrrolate intramus-
cularly, and the standard monitoring methods, which in-
cluded electrocardiography, non-invasive blood pressure
assessment, and pulse oximetry, were initiated after the
patients entered the operating room. First, 60-μg/kg
midazolam and 2-mg/kg propofol were administered
intravenously, followed by 0.6-mg/kg rocuronium after
confirmation of the patients’ loss of consciousness. There-
after, intubation was performed. In the palonosetron
group (group P), patients blinded to their group status re-
ceived 0.075 mg of palonosetron intravenously immedi-
ately after endotracheal intubation, whereas the patients
in group A received an equal volume of normal saline. An
independent anaesthesia assistant who was not involved
in either intraoperative or postoperative management pre-
pared the study medications. Desflurane with oxygen/
nitrous oxide in 0.5 FiO2 was administered at a 1.5–2
minimum alveolar concentration to maintain anaes-
thesia, and the ETCO2 was maintained at 35–40 mmHg.
For postoperative pain management, nefopam (20 mg)
was diluted in 100 mL of normal saline and administered
intravenously for 30 min, 10 min before surgery. Using
automated IV-PCA (Automed 3300; Ace Medical, Seoul,
Republic of Korea), 20-μg/kg fentanyl was diluted in nor-
mal saline for a total volume of 100 mL, set at a 0.2-μg/kg
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0.004-mg/kg glycopyrrolate and 0.2-mg/kg pyridostigmine
were administered intravenously to reverse any residual
neuromuscular block after restoration of spontaneous
breathing in all patients. All the anaesthetic procedures
were performed by a single anaesthesiologist who was
blinded to the patient group allocation.
PONV treatment completion was defined as a VAS
nausea score <4 for 48 h after surgery or non-use of ad-
ditional antiemetic drugs during this period. The VAS
score was used to quantify the severity of nausea in the
recovery room and 2, 6, 24, and 48 h after surgery.
When a patient experienced nausea at a VAS score >4
with retching or vomiting, 10 mg of metoclopramide
was administered intravenously. When symptoms did
not improve at follow-up, 5 mg of dexamethasone was
administered intravenously.
Postoperative pain management was standardised, and
patients were trained to press the IV-PCA button when
they experienced pain. The VAS score was used to repre-
sent the pain that patients experienced in the recovery
room and 2, 6, 24, and 48 h after surgery, and their con-
sumption of fentanyl in the IV-PCV was checked. If the
VAS score was ≥4, an additional 50 μg of fentanyl was
administered and recorded. Postoperative management
and data collection were conducted according to the
study protocol by another anaesthesiologist and a trained
member of the research group, respectively, who were
blinded to the patient groupings. The patients remained
unaware of their group affiliation until study completion.
This study aimed to demonstrate that aprepitant is
non-inferior to palonosetron in preventing PONV. A
pilot study was conducted among 40 patients who re-
ceived palonosetron, which reported a 35% incidence of
PONV 48 h after surgery. When the non-superiority
margin of aprepitant was set at 25% with an α value of
0.05 and statistical power of 80%, the required number of
patients for each group was 46. Considering that <10% ofFigure 1 CONSORT diagram.the patients were lost to follow-up, a total of 100 patients
were enrolled in the present study.
Repeated-measures analysis of variance was used for
the statistical analysis. For continuous variables, a t test
was used; for discrete variables, chi-square or Fisher exact
tests were used. PASW Statistics version 18.0 (SPSS
Inc., IBM Corporation, Chicago, IL, USA) was used
for the analysis, and P < 0.05 was considered statisti-
cally significant.
Results
This study was conducted between October 2011 and
September 2013 at the Chung-Ang University Hospital,
Seoul, Republic of Korea. Among the 100 subjects en-
rolled in this study, 93 were included in the analysis, be-
cause 3 patients voluntarily stopped using IV-PCA, 2
switched to laparotomy during the laparoscopy, and 2
received other drugs in the ward (Figure 1). No signifi-
cant differences were observed in the patients’ demo-
graphic data between groups P and A, including the
surgical duration, age, height, and weight (Table 1).
Thirteen of the 47 patients (27.7%) in group P and 13
of the 46 patients (28.2%) in group A received meto-
clopramide as an antiemetic medication, of which 2
patients in group P and 1 patient in group A received
dexamethasone. The treatment completion rates were
72.3% and 71.8%, respectively, without significant differ-
ence (Table 2). The nausea intensity in the recovery
room and 2 h after surgery assessed using the 10-point
VAS was significantly lower in group A (11.2 ± 2.1 and
9.7 ± 2.1, respectively) than in group P (19.0 ± 2.2 and
19.4 ± 3.5, respectively; P < 0.05). However, the results at
6, 24, and 48 h after surgery did not differ significantly
(Figure 2).
The pain intensity, also measured using a 10-point
VAS, was also not significantly different throughout the
study period (Figure 3). Fentanyl consumption via auto-
mated IV-PCA was significantly lower in group A than
Table 1 Characteristics of the patients who underwent
laparoscopic gynaecologic surgery and antiemetic
therapy with either 0.075 mg of palonosetron (group P)





Operative time, minutes (mean ± SD) 79.2 ± 42.2 71.5 ± 37.7
Age, years (mean ± SD) 37.6 ± 8.0 37.9 ± 11.1
Height, cm (mean ± SD) 159.6 ± 5.1 160.5 ± 5.4
Weight, kg (mean ± SD) 54.8 ± 5.8 56.2 ± 5.6
The data are expressed as mean ± SD.
No significant differences were observed between groups P and A.
Figure 2 Severity of nausea over 48 postoperative hours,
graded using a 10-point visual analogue scale (VAS), in the
female patients who underwent laparoscopic gynaecologic
surgery. The data are expressed as mean ± standard error values of
the mean. *P < 0.05, compared with group P. Group P was given
0.075 mg of palonosetron intravenously, whereas group A was given
40 mg of oral aprepitant.
Moon et al. BMC Anesthesiology 2014, 14:68 Page 4 of 7
http://www.biomedcentral.com/1471-2253/14/68in group P at 2 and 6 h after surgery (Figure 4). Finally,
17 of the 47 patients in group P (36.2%) and 20 of the
46 patients in group A (43.5%) received additional fen-
tanyl. One patient in each group received fentanyl twice,
and 4 patients in group P and 3 in group A received fen-
tanyl thrice. No significant differences were observed in
the incidence and number of additional fentanyl admin-
istrations between the 2 groups (Table 3).
Discussion
The PONV treatment completion rate was 72.3% (34/47)
in group P and 71.8% (33/46) in group A. These data show
that aprepitant has the same PONV prevention effect as
palonosetron. Previous studies showed a wide range of
prevention effects of antiemetic drugs (22.9 − 77.8%), de-
pending on which drugs were administered for PONV
prevention in patients indicated for laparoscopic surgery
[11]. Park et al. [12] reported a 66% treatment completion
rate when palonosetron was administered for PONV pre-
vention in patients indicated for gynaecologic laparoscopic
surgery, and Jung et al. [13] reported 56% and 63% treat-
ment completion rates in the 80- and 125-mg aprepitant
groups, respectively.
The subjects in the present study were female non-
smokers who received opioids for postoperative pain and
were included in the high-PONV-risk group. Despite theTable 2 Rescue antiemetic administration





Total incidence 15 14
Total patients 13 13
The data represent the number of patients. Group P was given 0.075 mg of
palonosetron intravenously, whereas group A was given 40 mg of oral
aprepitant. The total number of patients excludes the number of patients with
repeated administration (2 patients in the palonosetron group and 1 patient in
the aprepitant group). No significant differences were observed between
groups P and A.risk factors, this study showed a higher PONV treatment
completion rate than other studies. One explanation for
this difference is that midazolam and propofol, which
were used to induce anaesthesia, might have helped pre-
vent PONV. Even a small dose of propofol is known to
have an antiemetic effect, and a previous study reported
that administration of 10 mg of propofol successfully
treated PONV [14]. Propofol is associated with a lower
PONV incidence than inhalation anaesthetics [15,16], and
Kim et al. [17] reported that combined administration
of a serotonin receptor antagonist and midazolam wasFigure 3 Severity of pain over 48 postoperative hours in the
female patients who underwent laparoscopic gynaecologic
surgery, graded using a 10-point visual analogue scale (VAS).
The data are expressed as mean ± standard error values of the
mean. Group P was given 0.075 mg of palonosetron intravenously,
whereas group A was given 40 mg of oral aprepitant.
Figure 4 Fentanyl consumption over 48 postoperative hours in
the female patients who underwent laparoscopic gynaecologic
surgery. The graph shows the changes in fentanyl consumption
according to the type of drug administered. The data are expressed
as mean ± standard error values of the mean. *P < 0.05, compared
with the palonosetron group. Group P was given 0.075 mg of
palonosetron intravenously, whereas group A was given 40 mg of
oral aprepitant.
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used in all the subjects in this study, which may explain
the low incidence of PONV compared with that in other
studies. Fentanyl is an opioid and represents the major
cause of PONV. Unlike in the studies by Park et al. [12]
and Jung et al. [13], in this study, the basal infusion dose
of fentanyl was not set via IV-PCA. Therefore, its dose
was reduced when our patients experienced less pain,
which might also explain the high PONV treatment com-
pletion rate in this study.
For the patients who still experienced retching or
vomiting and had a VAS score of ≥4 even after adminis-
tration of drugs for PONV prevention, multiple drug ad-
ministration was recommended for prevention [18]. Lee
et al. [19] recently reported more significantly reducedTable 3 Rescue analgesic administration





Total incidence 26 27
Total patients 17 20
The data represent the number of patients. Group P was given 0.075 mg of
palonosetron intravenously, whereas group A was given 40 mg of oral
aprepitant. The total number of patients excludes the number of patients with
repeated administration (5 patients in the palonosetron group and 4 patients
in the aprepitant group). No significant differences were observed between
groups P and A.nausea and vomiting in patients treated with a combin-
ation of ramosetron, a serotonin receptor antagonist,
and aprepitant than in patients treated with aprepitant
alone for 24 h. Aprepitant does not exhibit affinity for 5-
hydroxytryptamine, dopamine, or steroid receptors, to
which retching-related neurotransmitters bind [6]. As
such, palonosetron and aprepitant can be administered
together effectively to patients at high risk of PONV
owing to their different action sites. Palonosetron is ad-
ministered intravenously, whereas aprepitant is admi-
nistered orally. Patients who are subjected to general
anaesthesia have to undergo a period of fasting after
surgery, which renders the postoperative administration
of aprepitant difficult. Thus, preoperative oral administra-
tion of aprepitant and perioperative intravenous admi-
nistration of palonosetron in patients with nausea and
vomiting would likely result in a synergistic effect if the 2
drugs show similar effects when administered separately.
In this study, a lower dose of aprepitant (40 mg) was
used than in the study of Jung et al. [13]. A previous
study that provided the basis for determining the aprepi-
tant dose in this study reported that 80 mg of aprepitant
was suitable for patients undergoing chemotherapy,
whereas 40 mg was sufficient for PONV prevention [6].
Furthermore, Diemunsch et al. [20] reported that 40 mg
of orally administered aprepitant was more effective in
PONV prevention than ondansetron. In this study, we
also observed that 40 mg of aprepitant administered pre-
operatively was effective for PONV prevention.
Aprepitant selectively inhibits substance P from bin-
ding to the NK1 receptor [21]. Substance P expression is
observed more often in the dorsal root than in the ven-
tral root of the spinal cord. Lembeck suggested that sub-
stance P is a primary sensory neurotransmitter [22].
Substance P is also observed in smaller and unmyelin-
ated sensory fibres [23]. It is involved in pain stimulus
formation and is known to transmit pain. An animal
study reported decreased pain when aprepitant was ad-
ministered [10]. However, Hill et al. [24] reported that
the effect of NK1 receptor blockers on pain control re-
mains to be fully established in humans. In this study,
the VAS was used to measure postoperative pain inten-
sity, although the results in the palonosetron and aprepi-
tant groups did not significantly differ. The fentanyl
consumption in IV-PCA was significantly lower in group
A than in group P 6 and at 24 h after surgery. This re-
sult was similar to that of the study of Katuta et al. [25],
in which the analgesic requirement was lower even if the
pain severity did not significantly differ. A greater num-
ber of patients in group A (43.5%, 20/46) received an
additional administration of analgesic than that in group
P (36.2%, 17/47), although the difference was not statis-
tically significant. The effect of aprepitant on pain reduc-
tion was difficult to demonstrate.
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used propofol and midazolam to induce anaesthesia,
which might have affected the PONV incidence, as de-
scribed previously. However, although their pure an-
tiemetic effects were not measured, the same doses of
propofol and midazolam were used in the 2 groups to
enable comparison of the effectiveness of palonosetron
and aprepitant in PONV prevention. The absorption and
distribution of aprepitant can differ depending on the
dose and treatment duration. It takes approximately 3 h
for 40 mg of orally administered aprepitant to reach its
maximum blood concentration [6]. In this study, however,
aprepitant was administered 90 min before anaesthesia in-
duction, and the surgery duration differed among patients.
As such, the maximum blood concentration of aprepitant
might not have been reached in some of the patients at
surgery completion. However, the VAS nausea scores were
lower in group A until 2 h after surgery, which shows that
the timing of aprepitant administration did not signi-
ficantly affect the results. Moreover, complete allocation
concealment and double-blinding were difficult because of
the obviously different timing and drug administration
routes between the groups. To ensure that this did not in-
duce any bias in obtaining study outcomes, we adhered to
a rigorous study protocol, as described in the Subjects and
Methods. Finally, in the planning stage of this study, the
appropriate number of subjects was determined based on
the PONV treatment rate. More subjects could have been
enrolled for more accurate pain study results. The effect
of aprepitant on pain control can be assessed accurately in
future studies if the appropriate number of subjects is de-
termined based on pain intensity.Conclusions
In this study, aprepitant was as effective as palonosetron
for PONV prevention in patients who underwent gynae-
cologic laparoscopic surgery. However, the effectiveness
of aprepitant for postoperative pain control in relation
to substance P warrants further investigation.
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